Products was Ascentage Pharma Group International’s largest revenue line in fiscal 2025, bringing in $499.27M of $574.12M (87%).
| Products and services [axis] | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Intellectual Property Income | — | — | $678.42M | — |
| Products | $174.93M | $193.54M | $260.84M | $499.27M |
| Commercialization Rights Income | $24.36M | $26.05M | $37.49M | $72.63M |
| Others | $10.42M | $2.40M | $3.92M | $2.22M |
| Total | $209.71M | $221.98M | $980.65M | $574.12M |
Ascentage Pharma Group International brought in $574.12M from its three revenue lines in fiscal 2025, the year ended December 31, 2025. Ascentage Pharma Group International regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $980.65M. Products was the largest at $499.27M (87.0%), ahead of Commercialization Rights Income at $72.63M (12.7%) and Others at $2.22M (0.4%).
Compared with fiscal 2024, Commercialization Rights Income grew 93.8% to $72.63M and Products grew 91.4% to $499.27M. From fiscal 2022 to 2025, combined revenue from these revenue lines grew from $209.71M to $574.12M, a compound annual growth rate of 39.9%. Products' share of the total rose from 83.4% to 87.0%.
Ascentage Pharma Group International stopped reporting Intellectual Property Income as a separate revenue line after fiscal 2024, when it brought in $678.42M.
Ascentage Pharma Group International (AAPG) reports its revenue by products and services [axis]. In fiscal 2025, Products was its largest revenue line, bringing in $499.27M (87.0% of the total), followed by Commercialization Rights Income at $72.63M (12.7%).
Products was Ascentage Pharma Group International's largest revenue line in fiscal 2025, bringing in $499.27M, or 87.0% of the $574.12M total across its three revenue lines.
Every figure comes from Ascentage Pharma Group International's annual financial filings, as reported. Each line keeps the name Ascentage Pharma Group International gives it, and years follow its fiscal calendar.
Ascentage Pharma Group International's revenue by products and services [axis] goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.